Among the estimated 235 million people worldwide who have asthma,1 a sizable portion are unable to achieve adequate disease control without high doses of inhaled corticosteroids (ICS) and/or oral corticosteroids, or are generally unresponsive to these therapies. These individuals, comprising approximately 5% to 10% of the total asthma population,2 are considered to have severe asthma.…
An increased right to left ventricle diameter ratio may help identify high-risk patients with suspected interstitial lung disease/pulmonary hypertension.
The FDA Arthritis Advisory Committee voted 10 to 7 in favor of approval of Ofev for the treatment of systemic sclerosis associated with interstitial lung disease.
In patients with myositis-related interstitial lung disease, azathioprine and mycophenolate mofetil treatment offers clinical improvements and a reduction in prednisone dose.
Including Cystic Fibrosis Foundation Patient Registry variables in the lung allocation score calculation allowed for enhanced discrimination of disease severity and improved access in patients with cystic fibrosis as well as COPD.
Patients taking the antifibrotic medications nintedanib and pirfenidone for idiopathic pulmonary fibrosis had reduced all-cause mortality and hospitalizations for up to 2 years compared with a matched untreated cohort.
In patients with idiopathic pulmonary fibrosis, anorexia and weight loss during prior treatment with pirfenidone was associated with early termination of subsequent nintedanib therapy.
Researchers conducted both serologic and tissue expression tests which revealed that for rheumatoid arthritis-associated interstitial lung disease immune responses from anti-malondialdehyde acetaldehyde adducts modified proteins may serve as biomarkers.
